PM Modi, Trump Could Meet At G7 Summit In France, Key Talks On Trade Deal, Quad Likely
Possible Modi-Trump meeting at the G7 Summit in France may focus on trade deadlock, Quad agenda and key global conflicts amid evolving India-US ties.
๐ฎ๐ณ ์ธ๋ ยท "POSSIBLE" ยท ์ด 58๊ฑด
ํํฐ ๋ณด๊ธฐํ์ฌ ์ง์
50.0
0 = ๋ถ์ ์ฐ์ธ
50 = ์ค๋ฆฝ
100 = ๊ธ์ ์ฐ์ธ
์ต๊ทผ 7์ผ ๊ธฐ์ค 5,756๊ฑด์ ๋ถ์ํ ๊ฒฐ๊ณผ, ๋ด์ค ์ฌ๋ฆฌ์ง์๋ 50.0(๊ท ํ)์ ๋๋ค. ๊ธ์ 0๊ฑด(0.0%)ยท์ค๋ฆฝ 5,756๊ฑด(100.0%)ยท๋ถ์ 0๊ฑด(0.0%)์ด๋ฉฐ, ์ค๋ฆฝ ๋น์ค์ด ๋๋ ทํ๊ฒ ๋์ต๋๋ค. ์ฑํฅ ์ง์๋ ์ข ํฉ 0.0(์ค๋ ๊ท ํ)์ ๋๋ค.
Possible Modi-Trump meeting at the G7 Summit in France may focus on trade deadlock, Quad agenda and key global conflicts amid evolving India-US ties.
More than two lakh applicants opted to pay USD 100,000 for their H-1B visas to work in the US in the fiscal year 2026, Markwayne Mullin, Secretary, Department of Homeland Security (DHS), said here.Testifying before the Senate Appropriations Subcommittee on Tuesday, Mullin said the DHS had received about 2.86 lakh H-1B applications in the fiscal year 2026."We had 286,000 applicants a year to date for the H-1B visas, out of those, over 200,000 of them paid USD 100,000 to be able to come in because it allows us to process them in a little bit faster of a manner," Mullin said in response to a question by US Senator Susan Collins on the shortage of doctors in rural parts of the country.Mullin said applicants paying USD 100,000 get their papers processed in about 15 days and it takes about 7.5 months to process other applications.Collins told the subcommittee that a hospital in Presque Isle, a rural community in northern Maine, recently had to pay the fee to secure a much-needed surgeon from overseas.She said that medical service providers serving remote areas should be treated differently from employers recruiting highly skilled workers in sectors with larger domestic labour pools."Would you be willing to consider carving out an exemption for medical professionals from this fee when a community can demonstrate that there is not a medical professional available?" Collins asked.Mullin assured the Senator that he would look at possible solutions on whether such applications could be dealt with some flexibility on a case-by-case basis."I would suggest that there's a huge difference between bringing in a computer expert from another country to work in wealthy California and Silicon Valley versus a much-needed surgeon to work at a rural hospital in northern Maine," she said.Republican Senator from Alaska Lisa Murkowski flagged concerns about the shortage of teachers in school districts in rural areas of her state."I'll follow up with you about the issue that I raised previously with regards to H-1B visas for teachers," Murkowski told Mullin.
WMO forecasts suggest a strong El Nino is possible.
He said he has consulted with the Electricity Minister regarding possible power outages during rains
Tourists planning a trip to Thailand this week may need to prepare for wet weather, possible travel disruptions and rough sea conditions, as the country's meteorological agency has forecast widespread rainfall and thunderstorms across several regions. According to the Thai Meteorological Department (TMD), a strong south-west monsoon over the Andaman Sea, Thailand and the Gulf of Thailand, combined with a low-pressure system off the coast of Vietnam, is expected to bring persistent rain across the country on June 2. Authorities have warned of heavy rain in several provinces and very heavy rainfall along parts of Thailand's west coast in the south. The weather conditions could trigger flash floods and runoff in low-lying areas and locations near waterways. Which tourist areas could be affected? Popular destinations on Thailand's west coast, including Phuket, Krabi, Phang Nga, Trang and Satun, are expected to see the heaviest rainfall, with thunderstorms forecast across 80% of the region.131421089 In eastern Thailand, tourist destinations such as Pattaya and coastal areas in Rayong and Trat could also experience thunderstorms and periods of heavy rain. The forecast for Bangkok and surrounding areas indicates thunderstorms in around 60% of locations, with isolated heavy downpours possible. What should island-hoppers and beachgoers know? Travellers planning boat trips, island tours or water activities should closely monitor local weather advisories. The TMD has warned of rough seas in both the Andaman Sea and the Gulf of Thailand. Wave heights in the upper Andaman Sea, including waters around Phuket, are expected to reach 2-3 metres and could exceed 3 metres during thunderstorms. In the lower Andaman Sea, including waters near Krabi and southern islands, waves could rise above 2 metres during storms. Authorities have advised vessels to proceed with caution and avoid sailing through thunderstorm zones. Small boats in the upper Andaman Sea have been advised to remain ashore. How could the weather affect travel plans? Heavy rain may lead to delays for ferry services, island excursions, outdoor sightseeing and adventure activities. Tourists visiting beaches, national parks and mountainous areas should be alert to local weather warnings, particularly in regions vulnerable to flash flooding.
Social media users are concerned about hackers stealing fingerprints from peace sign selfies, a fear amplified by viral posts. While experts confirm it's theoretically possible to extract fingerprints from high-resolution photos, the real-world risk for average users is minimal and less concerning than existing cyber threats like phishing.
Foreign travellers entering, leaving, or transiting through Vietnam will be required to submit a health declaration before travel from July 1, 2026, under new government regulations aimed at monitoring infectious disease risks. According to a report by Fragomen, the expanded requirement will apply to all travellers entering, departing from, or transiting through Vietnam. Individuals will need to complete a health declaration within seven days before their travel date. The Vietnamese Ministry of Health will decide when and for which infectious diseases the requirement will be enforced. The decision will be based on global disease trends and the risk of diseases being imported into the country. Authorities have not yet announced how travellers will submit the declaration. Details about the platform and application process are expected in future guidance. Employers and travellers should prepare for possible delays when the new system is introduced, as authorities and passengers adjust to the requirement, as per Fragomen report.129876802New travel requirement follows Ho Chi Minh City airport trial Foreign nationals arriving at Tan Son Nhat International Airport in Ho Chi Minh City have already been subject to a similar requirement since April 21, 2026. Under the pilot programme, travellers must complete an online declaration form within three days before arrival. Immigration processing delays were expected through the end of April as authorities and passengers adjusted to the new system.Vietnam introduced the digital arrival card system to streamline arrival procedures and reduce waiting times at immigration counters as part of broader efforts to modernise border management and digitise entry processes.
Tariffs on agricultural equipment cut to 15% with possible 10% for US steel content, effective June 8.
Stunned by the massive fine, social media users said it is โnot possible to waiveโ and suggested she pay it at the earliest to avoid being blacklisted for the next Schengen visa.
Posters put up by supporters in Madurai and growing social media buzz have intensified speculation over Annamalaiโs political future and possible next move in Tamil Nadu.
A more plausible reason for Congressโs keenness to ally with the BSP could be a possible alliance also in Punjab and Uttarakhand as well
Nifty remains in a broad consolidation phase, with support clustered around 23,200โ23,300 and resistance near 23,750โ24,050, leaving traders watchful for a decisive breakout. While the broader structure stays constructive and buy-on-dips strategies are favoured, sentiment is tempered by repeated hurdles and late-week volatility, keeping the index range-bound with a cautiously positive undertone.DHARMESH SHAH HEAD OF TECHNICAL RESEARCH AT ICICI SECURITIESWhere is Nifty headed this week? The index is undergoing a healthy consolidation in the 23,800-23,200 zone that has set the stage to gradually head toward the 24,500 level in the coming weeks. Strong support is placed at 23,200. Some of the key observations are: Banking, auto, capital goods sectors have set a higher base while the IT sector is showing signs of revival near its decade-long support line. Brent crude oil has broken down below its one-month rising trendline support. Stocks above 50-day and 200-day SMAs within Nifty 500 rose to 68% and 45%. Nifty Midcap index broke out of a three-week consolidation to hit new record highs. Small-cap index bounced off its 52-week EMA base and sits 8% below all-time highs. Trading strategy: Decline towards 23,300-23,400 (Nifty Spot levels) should be used as a buying opportunity for a target of 23,900.TOP BETS FOR THE WEEK Tata Power: Buy at Rs 410-424, stop loss at Rs 392, target Rs 470The stock is rebounding after retesting the April 2026 breakout area of Rs 415. As per the change of polarity principle, the previous resistance is now acting as a strong support, offering a fresh entry opportunity with a favourable risk-reward setup. Sona BLW Precision Forgings: Buy at Rs 600โ610, stop loss at Rs 588, target Rs 660. The stock has witnessed a cupand-handle breakout retest pattern, indicating inherent strength. It is now forming a higher-base formation while sustaining above its cluster of moving averages, signalling a revival of structure in the larger-degree time frame 131431542TANMAY SHAH RESEARCH HEAD, SIHLWhere is Nifty headed this week? Nifty remains in a broad consolidation range of 23,200โ24,050 with a positive undertone, as long as it sustains above the crucial 23,200 support on a closing basis. Traders can adopt a buy-on-dips strategy with stops at 23,250 and targets near 24,200, though a decisive close below 23,200 would weaken the bullish structure and trigger profit-booking. Trading strategy: Traders with a moderately bullish outlook may consider a Bull Call Spread for the 9th June expiry by buying the 23,700 Call and simultaneously selling the 24,050 Call. The strategy offers a favourable risk-reward profile of nearly 1:2 while limiting downside risk, making it suitable for the current range-bound yet positive market setup. TOP BETS FOR THE WEEK: L&T: Buy at CMP Rs 4,074, stop loss at Rs 3,950, target Rs 4,240- 4,400. L&T trades firmly above its key moving averages, with a rising RSI and a bullish weekly structure, indicating a favourable risk-reward setup at current levels. Indian Energy Exchange: CMP Rs 128.31, stop loss at Rs 124.50, target Rs 134-139.80. The stock has formed a bullish double-bottom near its 50-day moving average, backed by strong volumes.SUDEEP SHAH HEAD - TECHNICAL AND DERIVATIVE RESEARCH, SBI SECURITIESWhere is Nifty headed this week? Nifty remains trapped in a broad consolidation phase, with the monthly chart reflecting indecision through a bearish candle and near-term sentiment tilting slightly bearish after Fridayโs late sell-off, though indicators still lack trend strength. The immediate hurdle lies at 23,750โ23,800, while support at 23,300โ 23,250 is crucialโbelow which a slide to 23,000 is possible, whereas a move above 23,800 could revive short-term bullish momentum. Trading strategy: Since the Index is trading in a broader range with volatility, we advise traders to go long on Nifty only on a breakout above 23,800 with a stop loss at 23,500 for a target of 24,250. TOP STOCKS FOR THE WEEK Nuvama Wealth Management: CMP Rs 1,554, stop loss at Rs 1,480, target Rs 1,690-1,750. The stock continues to display a strong price structure, trading above key moving averages across timeframes and reflecting sustained bullish momentum. After a healthy consolidation, it has broken out with buying visible on dips, while relative strength against peers and the broader market remains favourable. Syrma SGS Technology: CMP Rs 1,088, stop loss at Rs 1,045, target Rs 1,160-1,180. Syrma remains in a strong uptrend, outperforming peers in the EMS space and holding firmly above key moving averages with sustained buying interest on dips. Momentum indicators stay supportive, and improving relative strength versus the broader market points to further upside potential.
For Gujarat Titans, this was supposed to be Ahmedabad's night.Instead, it became an Ahmeda-bad evening for Shubman Gill's men.Also Read: RCB win IPL for 2 straight years, but this player has created a hat-trick of winsOn a stage draped in blue, in front of a crowd willing the home side towards a second IPL crown, Royal Challengers Bengaluru once again arrived like champions who no longer carry the burden of history. They carried certainty. They carried belief. And, as they have so often over the last two seasons, they carried Virat Kohli.Chasing a modest but tricky 156, RCB were never reckless. They were relentless. Kohli, the grandmaster of the chase and the heartbeat of this franchise, produced yet another knockout innings, crafting a half-century that sucked the anxiety out of the contest and the hope out of Gujarat's defence. It was not his most explosive knock. It did not need to be. It was a classic Kohli pursuit โ measured, intelligent and utterly inevitable.The numbers will show another fifty. The final will remember much more than that.For a franchise that spent nearly two decades being cricket's great unfinished story, this felt like the final confirmation that last year's title was not an emotional one-off. This is now a team that understands how to win the biggest games. Two titles in two years is not a breakthrough. It is the beginning of a legacy.Yet Gujarat refused to make it easy.After being restricted to 155, a total that always felt 20 runs short on a placid Ahmedabad surface, the Titans fought with the stubbornness that has defined much of their short IPL history. Rashid Khan, magnificent as ever, dragged the contest deeper than it deserved to go. His spell was a reminder that class survives even when the scoreboard does not cooperate. Every wicket he took briefly reignited belief. Every dot ball lifted the noise levels.Also Read: Rohit, Dhoni, Hardik: When IPL's biggest names couldn't deliver this seasonAnd then there was Rajat Patidar โ the quiet captain who has turned Royal Challengers Bengaluru from cricketโs great underachievers into a title machine.A year after leading RCB to their long-awaited maiden IPL crown, Patidar is set to script history again, becoming only the third captain after MS Dhoni and Rohit Sharma to guide a franchise to back-to-back IPL titles. If last season was about breaking an 18-year curse, this one has been about building a champion's mentality.Patidarโs numbers do not scream for attention, but his captaincy has. RCB topped the league stage, steamrolled Gujarat Titans in Qualifier 1, and entered the final carrying the assurance of a side that no longer panics under pressure. The 31-year-old has fostered a dressing-room culture built on clarity and calm, repeatedly insisting throughout the season that every game was โjust another matchโ despite the mounting expectations around a title defence.His fingerprints were all over the campaign. Whether it was trusting Josh Hazlewood in crunch overs, backing Krunal Pandya's experience on spin-friendly surfaces, or ensuring Virat Kohli could play the anchor's role without the burden of forcing the pace, Patidar's tactical calls consistently landed. Most importantly, Patidar has managed something few RCB leaders before him could: he has made the franchise feel bigger than its baggage. For years, RCB were defined by near-misses, heartbreaks and dependence on individual brillianceBut Gujarat's bowlers were left carrying a burden that should never have been theirs alone.The real disappointment lay with the batting.Too many starts disappeared. Too many big names drifted through the final without leaving a mark. At no point did the innings gather the momentum expected from a side stacked with stroke-makers and match-winners. The scoreboard moved, but never surged. The pressure remained, and RCB's attack, led by the discipline of Josh Hazlewood and the control of Krunal Pandya, squeezed relentlessly.By the halfway mark, the script already felt familiar.RCB had been the better side for most of the season. They entered the final as favourites. They played like favourites. And when the moment arrived to finish the job, they handed the chase to the one man who has spent nearly two decades making impossible pursuits look routine.Kohli has worn many labels across his career โ superstar, run machine, icon, leader.On nights like these, one title fits best- King Kohli.And with another IPL trophy glistening under the Ahmedabad lights, his kingdom just got bigger
New Delhi: Defeat on the mat did not make Vinesh Phogat feel like a loser.After her comeback bid ended in the Asian Games selection trials on Saturday, the former world championships medallist declared that she had already won by returning to competition after motherhood and by standing up to a system she claimed had done everything possible to keep her away from wrestling."I have not failed at all. I am fighting the whole system and I am still standing with pride on the mat again," Vinesh toldafter her 4-6 semifinal loss to Meenakshi Goyat, while reiterating her ambition of competing at the 2028 Los Angeles Olympics.Minutes after suffering defeat, Vinesh launched a scathing attack on the wrestling administration, alleging discrimination, mental harassment and attempts to block her return to competitive wrestling despite court orders in her favour.Also read | IPL 2026 Purple Cap winner list: Most wickets, updated standings and bowling rankings"They wanted to stop me from returning to the mat, but I am standing here again. I am proud of what I have achieved in these 10 months."I know the system will continue to create challenges for me, but I have hope that through hard work I can leave the system behind and move forward," she added, refusing to view the semifinal defeat as a setbackVinesh, who was competing for the first time since her heartbreaking disqualification from the Paris Olympics final in 2024, said her biggest achievement was returning to elite competition after childbirth. She said returning to competition after motherhood and after months of legal and administrative battles felt like a victory."It has been only 10 months since my son was born. I am standing on the mat again and competing against the younger generation. I am proud of myself. I hope I can inspire my son and many women wrestlers," she said.Vinesh described the Delhi High Court order that enabled her participation in the trials as a landmark moment for women wrestlers seeking to return after motherhood."A girl is coming back to the mat after becoming a mother. The path has opened. Sooner or later there has to be a policy. Women wrestlers who want to return after becoming mothers should get a fair opportunity and some relaxation," she said.The 31-year-old alleged that even after the court's intervention, officials continued to create obstacles for her.Also read | Liverpool sack Slot after title defence turns into European scrambleShe said that she spent nearly an hour arguing with officials on Saturday morning after being informed she would be allowed to compete only in the 50kg category despite wanting to participate in 53kg."When I should have been focusing on my recovery and preparation, I was arguing with officials. They gave me a letter saying I could compete only in 50kg. It was mental harassment," she said.Vinesh claimed that the entire process was designed to put her at a disadvantage, alleging that stronger wrestlers were deliberately placed in her draw and that scheduling decisions drained her energy before the semifinal."I was not given a fair deal. All the strong girls in my category were put in my path. The bouts were scheduled in a manner that affected my energy levels," she alleged.Despite the grievances, Vinesh accepted responsibility for her defeat and admitted that a lack of competitive exposure and endurance hurt her performance."I accept my defeat. I will work harder and return stronger. Fitness and endurance were issues, but more than that, I needed competitions. I had not competed for nearly two years. This was my first tournament after becoming a mother," she said.She insisted that Saturday's performance convinced her that she still has enough ability to compete with the country's best wrestlers."I was motivated today. I know I can beat the younger girls. I still have that courage and belief. If I work hard, I know I can come back stronger."Asked whether the 2028 Los Angeles Olympics remained a target, Vinesh replied in the affirmative."Definitely. I have come back to the mat for Los Angeles," she said.The wrestler reserved some of her strongest criticism for the sports administration, questioning why no institution had intervened despite repeated disputes surrounding her participation."The government, the Sports Ministry, the IOA -- nobody is taking a stand. This is very sad. If athletes have to survive despite the system, then something is seriously wrong," she said.She also alleged that many young wrestlers privately supported her but were afraid to speak openly against administrators."A lot of girls were happy to see me back on the mat. They come and talk to me but they are scared. They know what can happen if they speak against powerful people," she said.Vinesh, however, clarified that she has no complaints against fellow wrestlers and said athletes should not be blamed for the larger issues within the sport."The kids are not at fault. I don't have anger towards any athlete. The problem is with the people who manipulate and control the system," she said.
A new Rafael Nadal documentary shows us an old, now unpopular way of building a legacy โ powering through suffering and impossible odds
Army Chief General Upendra Dwivedi says Operation Sindoor continues with a temporary halt in fighting and forces prepare for possible Operation Sindoor 2.0.
Karnataka Congress CLP meets to pick DK Shivakumar as new CM, US Iran talks near possible deal, Myanmar President U Min Aung Hlaing visits India, Arsenal face PSG in UCL final
Mumbai: A prolonged West Asia conflict represents a key downside risk to India's economic outlook according to the Reserve Bank of India (RBI), even as it projected a lower real gross domestic product (GDP) growth of 6.9% for 2026-27 in its annual report compared with 7.6% estimated for the previous financial year.The central bank said the impact of the conflict is likely to remain contained in the near term but warned that an escalation could derail India's otherwise positive growth trajectory."Going forward, India's growth outlook remains positive, though the West Asia conflict and the attendant risks of elevated energy prices, supply chain disruptions, financial market volatility, uncertainty surrounding global trade policies and weather-related disruptions could pose headwinds to growth and inflation in the short run," the Reserve Bank said.Also Read: Iran war - PSBs asked to stay preparedPositive Macro OutlookIt listed healthy corporate and bank balance sheets, government's continued thrust on capital expenditure and the implementation of trade agreements with key partners as positives to help sustain investment and growth momentum."Nevertheless, in a highly uncertain global environment, continuous assessment of the evolving developments is warranted to frame the appropriate policy response on an ongoing basis," the report said.131398139The central bank said that although portfolio flows exhibited a net outflow in 2025-26, strong buffers in the form of ample foreign exchange reserves and modest external debt liabilities continue to impart strength to the external sector, contributing to overall macroeconomic and financial stability.Adequate food grain stocks, sufficient reservoir levels and stable agricultural prospects despite possible El Nino conditions and above-normal summer temperature will keep inflation aligned to the target in 2026-27, according to the RBI. However, upside risks may emanate from a surge in global fuel and commodity prices amid geopolitical tensions, potential spillovers to input and wage costs and volatility in exchange rates.Also Read: India-US trade pact may be weeks away - US Ambassador to India Sergio GorThe central bank projected consumer price inflation for 2026-27 at 4.6%, with risks tilted to the upside, significantly higher than its revised estimate of 3.7% for the previous fiscal.Pressure on BondsDomestic bond yields could face upward pressure if the global monetary easing cycle stalls or reverses in response to persistent oil price shocks amid fragile conditions in West Asia, it said.Geopolitical risk has re-emerged as the dominant drag on global growth in 2026, according to the RBI. "In IMF's baseline scenario, the global economy is projected to grow by 3.1% in 2026 (as against the earlier projection of 3.3% in January), while global merchandise and services trade volume is expected to decelerate to 2.8% in 2026. Further intensification of the conflict, its prolongation or widening geographical spread, if any, remain the key downside risks to the global economic outlook," the report said."However, the government's commitment to fiscal consolidation, along with the liquidity injection measures by the Reserve Bank, is expected to contain the upward pressure on yields. Equity market dynamics would be conditioned by evolving geopolitical developments, global financial market volatility and foreign portfolio investment flows; a deterioration in risk sentiment alongside strengthening of the US dollar could trigger capital outflows," said the RBI's annual report. "At the same time, ongoing efforts to expand local currency settlement framework are expected to further advance rupee based cross-border transactions."
One of the biggest advances in pancreatic cancer in decades came out of a crazy idea born in a Harvard University lab.Chemical biologist Gregory Verdine believed you could fight disease-causing proteins hidden inside cells by chemically gluing them to something else in the body and smothering them."Everybody told us this is crazy, that it would never work," he recalls.Revolution Medicines, which bought one of Verdine's companies in 2018, recently announced that one of its drugs doubled the typical survival time for patients with aggressive forms of the disease, from 6.7 months to 13.2 months. The full results from the company's final-stage trial are expected to be the star of the show at the annual confab of cancer doctors in Chicago this weekend.Spurred by the success of RevMed, numerous companies are now racing to develop similar drugs, dubbed "molecular glues", which can be used to treat a variety of ailments. And investors and pharmaceutical companies with deep pockets are chasing after them, creating one of the hottest corners of dealmaking in the industry.Also read | India's out-of-pocket healthcare spending drops significantly, govt data showsIt's not unusual for exciting new drugs to spark surges in stock prices and dealmaking frenzy. But molecular glue is a particularly complicated science, and the startups pursuing technologies similar to RevMed are mostly in early stages of testing. Their medicines won't be ready for years, if ever.That hasn't stopped big drugmakers such as Novartis, Roche Holding and Eli Lilly from inking research pacts with glue developers that could pay out billions of dollars in milestones.The boom has been especially lucrative for Monte Rosa Therapeutics. Over the past three years, the Boston-based biotech firm has signed three agreements that could be worth over $10 billion to develop molecular glue drugs with both Novartis and Roche.The company, which trades under the stock ticker GLUE, has seen its shares surge nearly 400% over the past year. It's preparing to start mid-stage trials for multiple drugs by the end of this year."The run-up in the share price is justified based on what we've seen so far," says Robert Driscoll, an analyst at Wedbush. Gains are "due to the success of their drugs rather than kind of exuberance around the glue technology as a whole", he says.Science of GlueMolecular glues work in a fundamentally different way from other oral medicines. Most pills - like Prozac for depression or Lipitor for cholesterol - are tiny chemicals that squeeze into a pocket inside a much larger protein to gum up its functioning. But many proteins have few obvious pockets, including key cancer-causing proteins.In fact, about 80% of all proteins in the body are what scientists refer to as "undruggable", meaning they can't be targeted with traditional drug technologies.RevMed's daraxonrasib cleverly circumvents this problem by acting as a molecular stickum. Once inside the body it binds to a healthy protein on one side and then draws in the bad protein to stick to the other side. The healthy protein helps block the bad protein and turn off its signalling.Competitors Line UpMultiple companies are chasing RevMed's lead in pancreatic cancer despite the long odds. San Diego-based Erasca is in early stages of testing a drug it says is more potent than daraxonrasib. Japanese drugmaker Astellas Pharma has begun final-stage trials of a degrader that may help a subset of pancreatic and lung cancer patients.Molecular glues are also being developed as alternatives to injectable drugs used to treat autoimmune and skin disorders. Shares of Kymera Therapeutics have soared more than 180% in the past year thanks to promising early trial results. The company is developing a once-daily pill it hopes will one day compete with Sanofi and Regeneron Pharmaceuticals' Dupixent, one of the world's bestselling drugs."The technology allows you to go after things that would have been almost impossible" to do previously with pills, says Nello Mainolfi, Kymera's founder and CEO.With few effective options for pancreatic cancer, analysts expect RevMed's daraxonrasib to become an enormous bestseller for the company.Prospects for daraxonrasib and speculation about a potential takeout deal have inflated RevMed's market cap to nearly $33 billion. That's a lofty figure for a drugmaker with no approved medicines.The company is preparing to file for US approval soon, and the FDA has promised to give the drug an ultrafast review. It's projected to reach $7 billion in sales a year by 2032, according to the average of estimates compiled by Bloomberg.